In vitro effect of bioactive natriuretic peptides on perfusion pressure in placentas from normal and pre-eclamptic pregnancies.
The number of placental vascular guanylate-coupled receptors. corresponding to bioactive natriuretic peptide receptors is greater in preeclampsia. but there are no clear data about atrial natriuretic peptide (ANP) concentration in preeclampsia. The influence of various doses of ANP and urodilatin (URO) on placental perfusion pressure in preeclampsia was investigated by perfusing 16 human placentas in vitro. The placental vessels were submaximally preconstricted by continuous infusion of N-omega-nitro-L-arginine (NOLA). Perfusion pressure was measured continuously. Over 180 min various doses of alphaANP or URO were administrated (25, 50, 100, 200 nmol/l, 2 min increments). The effects of pretreatment with the guanylate cyclase inhibitor, LY 83583 was also examined. We found that ANP and URO attenuated NOLA-induced vasoconstriction, that URO given in higher doses produced stronger vasocilation than ANP, and that the mean decrease of perfusion pressure was higher in preeclampsia. The possibility of a non cGMP-mediated pathway of ANP and URO action should be considered.
Szukiewicz
D
D
Dept. of General & Experimental Pathology, Medical University School, Warsaw, Poland.
Szukiewicz
A
A
Maslinska
D
D
Markowski
M
M
D009320:Atrial Natriuretic Factor / Q000502:physiology*; D004867:Equipment Design; D005260:Female; D006162:Guanylate Cyclase / Q000037:antagonists & inhibitors; D006801:Humans; D010920:Placenta / Q000098:blood supply*; D011225:Pre-Eclampsia / Q000503:physiopathology*; D011247:Pregnancy / Q000502:physiology*; D014655:Vascular Resistance
D009320:Atrial Natriuretic Factor; D006162:Guanylate Cyclase